Enhancing Benefit With Durvalumab in NSCLC After the PACIFIC Trial

Enhancing Benefit With Durvalumab in NSCLC After the PACIFIC Trial

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLCПодробнее

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

PACIFIC trial updates: durvalumab after chemotherapy in NSCLCПодробнее

PACIFIC trial updates: durvalumab after chemotherapy in NSCLC

Durvalumab Consolidation in NSCLC: The PACIFIC TrialПодробнее

Durvalumab Consolidation in NSCLC: The PACIFIC Trial

PACIFIC: Progression-Free Survival Increase in NSCLCПодробнее

PACIFIC: Progression-Free Survival Increase in NSCLC

Treating for Stage III NSCLC After Progression on DurvalumabПодробнее

Treating for Stage III NSCLC After Progression on Durvalumab

Post-hoc subgroup analysis from PACIFIC: durvalumab after CRT in unresectable stage III EGFRm NSCLCПодробнее

Post-hoc subgroup analysis from PACIFIC: durvalumab after CRT in unresectable stage III EGFRm NSCLC

PACIFIC 6: durvalumab after sCRT in patients with NSCLCПодробнее

PACIFIC 6: durvalumab after sCRT in patients with NSCLC

Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agentsПодробнее

Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agents

Examining Recent PACIFIC Trial Updates for Durvalumab in Locally Advanced NSCLCПодробнее

Examining Recent PACIFIC Trial Updates for Durvalumab in Locally Advanced NSCLC

5-year survival outcomes from the PACIFIC trialПодробнее

5-year survival outcomes from the PACIFIC trial

Is Durvalumab Curing Patients or Just Treating Metastatic Disease Earlier? (BMIC-025)Подробнее

Is Durvalumab Curing Patients or Just Treating Metastatic Disease Earlier? (BMIC-025)

Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLCПодробнее

Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLC

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLCПодробнее

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLCПодробнее

Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLC

Updated Results on PACIFIC Trial: Revise Who Should Receive Consolidation Immunotherapy? (BMIC-065)Подробнее

Updated Results on PACIFIC Trial: Revise Who Should Receive Consolidation Immunotherapy? (BMIC-065)

Locally Advanced NSCLC: Durvalumab and the PACIFIC TrialПодробнее

Locally Advanced NSCLC: Durvalumab and the PACIFIC Trial

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLCПодробнее

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC

Reactions to the PACIFIC Trial in Stage III NSCLCПодробнее

Reactions to the PACIFIC Trial in Stage III NSCLC

Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Standard of Care? (BMIC-024)Подробнее

Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Standard of Care? (BMIC-024)